Trigeminal Neuralgia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Trigeminal Neuralgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Unknown stages are 1, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Trigeminal Neuralgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Trigeminal Neuralgia - Overview
- Trigeminal Neuralgia - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Trigeminal Neuralgia - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Trigeminal Neuralgia - Companies Involved in Therapeutics Development
- Allergan Plc
- Biogen Inc
- KPI Therapeutics Inc
- Merz Pharma GmbH & Co KgaA
- PixarBio Corp
- Trigemina Inc
For more information about this report visit https://www.researchandmarkets.com/research/mjf2lj/trigeminal